check_circleStudy Completed
Bioequivalence
Bayer Identifier:
14845
ClinicalTrials.gov Identifier:
Not Available
EudraCT Number:
Not Available
EU CT Number:
Not Available
To establish the bioequivalence between riociguat tablet 1.0 mg intended to be marketed (# 502) and riociguat tablet 1.0 mg used for clinical samples (#512) in Japanese healthy adult male subjects
Trial purpose
Please see attached Study Results Summary below.
Key Participants Requirements
Sex
N/AAge
N/ATrial summary
Enrollment Goal
24Trial Dates
September 2010 - November 2010Phase
Phase 1Could I Receive a placebo
N/AProducts
Adempas (Riociguat, BAY63-2521)Accepts Healthy Volunteer
N/AWhere to participate
Status | Institution | Location |
---|---|---|
Completed | Osaka Pharmacology Clinical Research Hospital | Osaka, 532-0003, Japan |
Trial design
Trial Type
InterventionalIntervention Type
N/ATrial Purpose
N/AAllocation
N/ABlinding
Open LabelAssignment
Crossover AssignmentTrial Arms
N/A